"CYDY has roughly an 8 fold increase in patient population versus IMMU. However, IMMU enjoys an 18 fold increase in market capitalization over CYDY even though they are neck and neck in the approval process. As the story evolves we believe this disparity will resolve itself in short order. What is even stranger than the extremely low market cap of CYDY is that they have an HIV drug, which on its own merits could dethrone Gilead (NASDAQ: GILD). This is all the more reason for investors to pay attention to this rapidly evolving story. "

this is awesome!